Elanco Animal Health Incorporated (ELAN)

Market Cap	6.64B
Revenue (ttm)	4.45B
Net Income (ttm)	205.00M
Shares Out	494.35M
EPS (ttm)	0.41
PE Ratio	32.57
Forward PE	15.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,563,115
Open	13.29
Previous Close	13.31
Day's Range	13.18 - 13.47
52-Week Range	11.40 - 18.80
Beta	1.42
Analysts	Buy
Price Target	17.00 (+26.49%)
Earnings Date	Nov 7, 2024

About ELAN

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticid...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 20, 2018
• Employees: 9,800
• Stock Exchange: NYSE
• Ticker Symbol: ELAN
• Website: https://www.elanco.com

Financial Performance

In 2023, Elanco Animal Health's revenue was $4.42 billion, an increase of 0.14% compared to the previous year's $4.41 billion. Losses were -$1.23 billion, 1478.2% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for ELAN stock is "Buy." The 12-month stock price forecast is $17.0, which is an increase of 26.49% from the latest price.

Price Target

$17.0

(26.49% upside)

Analyst Consensus: Buy